A detailed history of Janus Henderson Group PLC transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 6,137,244 shares of RVMD stock, worth $270 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
6,137,244
Previous 4,640,218 32.26%
Holding current value
$270 Million
Previous $180 Million 54.41%
% of portfolio
0.15%
Previous 0.1%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.92 - $47.94 $55.3 Million - $71.8 Million
1,497,026 Added 32.26%
6,137,244 $278 Million
Q2 2024

Aug 14, 2024

BUY
$30.14 - $40.68 $21.9 Million - $29.6 Million
728,099 Added 18.61%
4,640,218 $180 Million
Q1 2024

May 15, 2024

BUY
$26.56 - $33.55 $45.5 Million - $57.5 Million
1,712,639 Added 77.87%
3,912,119 $126 Million
Q4 2023

Feb 14, 2024

SELL
$18.35 - $34.12 $757,102 - $1.41 Million
-41,259 Reduced 1.84%
2,199,480 $63.1 Million
Q3 2023

Nov 14, 2023

BUY
$25.17 - $35.05 $23.2 Million - $32.3 Million
922,897 Added 70.03%
2,240,739 $62 Million
Q2 2023

Aug 14, 2023

BUY
$20.28 - $27.0 $19.6 Million - $26.1 Million
965,014 Added 273.51%
1,317,842 $35.3 Million
Q1 2023

May 15, 2023

BUY
$20.76 - $30.09 $7.13 Million - $10.3 Million
343,212 Added 3569.18%
352,828 $7.64 Million
Q4 2022

Feb 14, 2023

BUY
$17.68 - $25.53 $170,010 - $245,496
9,616 New
9,616 $229,000
Q2 2022

Aug 15, 2022

SELL
$14.54 - $27.17 $140,572 - $262,679
-9,668 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$17.31 - $26.4 $34 - $52
2 Added 0.02%
9,668 $246,000
Q4 2021

Feb 14, 2022

BUY
$24.35 - $33.7 $235,367 - $325,744
9,666 New
9,666 $243,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.86B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.